When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Advances in surgical treatments of melanoma have changed how surgeons treat patients with melanoma. According to Richard L. Shapiro, MD, associate professor in the Department of Surgery at…
Christopher Hourigan, MD, PhD, associate professor at Johns Hopkins and principal investigator at the National Heart, Lung, and Blood Institute of the National Institutes of Health, highlights his…
In this double interview, Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, and Lyudmila A. Bazhenova, MD, of UC San Diego Health, provide insights into…
New techniques and technology advancements in the field of radiation oncology are the topics of discussion in this interview with Amin J. Mirhadi, MD, associate professor of radiation…
In this video, Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology for the Sidney Kimmel Cancer Center at Johns Hopkins Medicine, stresses…
Geoffrey Oxnard, MD, associate professor of medicine at Harvard Medical School, discusses the advancements in treatments for lung cancer over the past 10 to 15 years. Even though…
In an interview at the 18th British Thoracic Oncology Group (BTOG) 2020 congress, Sanjay Popat, BSc, MBBS, FRCP, PhD, of The Royal Marsden NHS Foundation Trust in London,…
Heather A. Wakelee, MD, thoracic oncologist and professor of medicine at Stanford University Medical Center, discusses the decisions that go into planning treatments for newly diagnosed, advanced stage…
Join Michael Hochman, MD, MPH, for the second episode of Updates in Slow Medicine. This installment discusses results from a recent study that raises the possibility that a…
Lyudmila A. Bazhenova, MD, professor of medicine at UC San Diego Health, discusses the lack of data on chemoimmunotherapy or monotherapy immunotherapy for treatment of ALK-fused non-small cell…
